Printable version: 
Fact sheet as of December 04, 2023
SEB Concept Biotechnology
The fund invests in equities and equity-related securities in the biotechnology sector across the world.
Fund manager:  Angelica Fatouros
Investment Philosophy

The fund manager believes that the equity market is efficient in the long term. However, from a short term perspective, the market's players tend as a whole to react at different pace to new information. This inertia can create beneficial investment opportunities, and be best exploited when the fund management is based on a structural and quantitative process – which, in combination with a long-term approach and limitations of the fund's transaction costs, can create added-value.

Key Facts
Base CurrencyEUR
Share ClassC (EUR)
BenchmarkNasdaq Biotechn...
Year of launch2008
Value at launch (EUR)27.48
Legal StructureUCITS
Fund Management CompanySEB Investment Management AB
Morningstar Rating (3 years) 31 Oct 2023
Turnover Ratio*0.66
* 12 months rolling, last updated 31 Oct 2023
The share class does not pay dividends; the return is reinvested
Management Fee1.50
Ongoing Charges*1.56
Entry FeeMax 5%
* The ongoing charges includes the management fee and constitutes payment for fund management, including marketing and distribution. The ongoing charges does not include transaction costs such as brokerage commissions on securities transactions.
Risk Measures*
Standard Deviation (Fund)15.7
Standard Deviation (Index)15.9
Tracking Error4.2
Active share **34.3
Sharpe Ratio-0.1
Information Ratio-0.2
* 36 months rolling, last updated 31 Oct 2023
** Active share measures the difference between the fund’s and the benchmark’s holdings. From 31 Oct 2023
Investment Process

Investment universe

The fund invests globally in the biotechnology sector with focus on the US. The biotechnology sector is regarded as less sensitive to economic fluctuations than many other sectors, and the yield is dependent to a great deal on medical progress and scientific advances. Since the fund invests outside Sweden, the fund's asset value is affected by fluctuations of the Swedish krona in relation to other currencies. The fund has the possibility to use derivative instruments.

Investment team

The fund is managed by the Global Equities team (QPM) within SEB Investment Management AB. The team, based in Stockholm, employs a rule-based systematic and disciplined investment process.


The fund only pursues exposure in liquid securities. A quantitative process forms the basis to distinguish and analyze biotechnology companies and identify those that have attractive growth potential, a good and sustainable financial position, and in general enjoy the confidence of the market. An analysis is also performed of each company's risk profile and how they individually affect the fund's aggregated risk structure.

Portfolio construction

When composing the portfolio, the manager focuses on selecting the most interesting equities within the biotechnology sector based on analysis methodology. Considerable weight is then placed on creating a well-balanced portfolio from a global perspective, and establishing a desired risk profile for the fund, while simultaneously limiting the related transaction costs.

Currency: EUR        |        NAV: 103.07 (12/4/2023)        |        AuM (M EUR) : 124.42 (10/31/2023)
SEB Concept Biotechnology (FundEUR)Nasdaq Biotechnology Index (Benchmark, )
 Fund EURBenchmark
Return % EURFundBenchmark
Accumulated since  
1 day0.91.1
1 month2.71.3
3 months-4.8-4.9
6 months-6.3-5.4
1 year-13.9-13.1
3 years-4.6-4.2
5 years-0.724.1
Year to date-7.2-7.2
Average annual growth  
3 years-1.6-1.4
5 years-0.24.4
CurrencyAdd benchmark
Open the calendar popup.
Open the calendar popup.
Largest Positions*
% of Total  
 % of Total
Vertex Pharmaceuticals Inc9.6
Regeneron Pharmaceuticals9.5
Moderna Inc4.2
Alnylam Pharmaceuticals Inc2.5
Argenx SE2.4
Seattle Genetics Inc2.3
Illumina Inc2.3
* Last updated 29 Sep 2023. Source: SEB
* Numbers are absolute, not relative
Geographic Allocation*
* Last updated 31 Oct 2023. Source: SEB
* Numbers are absolute, not relative
Other Information

As of 1 February 2021 the funds has a new fund manager. As of 2 November 2016, the fund´s Management company is SEB Investment Management AB.

This material is prepared by SEB and contains general information regarding financial instruments marketed, sold or solicited by SEB. SEB is the global brand name for Skandinaviska Enskilda Banken AB (publ), its subsidiaries and affiliated companies. Neither this material nor the products described in it are intended for distribution or sale in the United States or to US persons, and any such distribution is not allowed. The offering of shares or units in the funds may also be restricted in other jurisdictions. This document may not be used to make an offer or solicitation with respect to the sale of shares or units where such an offer or solicitation is unlawful. Although the information in this material is based on sources deemed by SEB to be reliable, SEB assumes no liability whatsoever for incorrect or missing information or for any loss, damage or claim arising from the use of this material. Past performance does not guarantee future performance. The value of investment funds and other financial instruments may rise as well as fall and there is no guarantee you will recover your original investment. If you or a fund invests in financial instruments denominated in a foreign currency, changes in currency exchange rates can affect the return on the investment. SEB makes no representation that funds whose share or unit classes aim at hedging the fund’s return from changes in currency exchange rates will succeed in achieving this. Any tax information in this material is based on regulations valid as per the date of this presentation and may be subject to change. Note that any tax information in this material is general. Kindly contact your SEB investment advisor for tax and investment advice appropriate for your situation. You are fully and solely responsible for your investment decision. This material is not intended for or suitable as the sole basis for investment decisions. Instead, you should base your decision on the information in the fund’s product documentation, including its fact sheet, Key Information Document, fund regulations and prospectus. These are available on
Tuesday, December 5, 2023 7:25:24 PM